Beyond Air (NASDAQ:XAIR – Get Free Report) and Orchestra BioMed (NASDAQ:OBIO – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability and institutional ownership.
Earnings & Valuation
This table compares Beyond Air and Orchestra BioMed”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Beyond Air | $7.68 million | 0.26 | -$33.25 million | ($68.40) | -0.03 |
| Orchestra BioMed | $33.48 million | 10.03 | -$52.70 million | ($0.85) | -6.58 |
Profitability
This table compares Beyond Air and Orchestra BioMed’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Beyond Air | -435.71% | -440.26% | -98.50% |
| Orchestra BioMed | -184.60% | -149.61% | -54.15% |
Risk & Volatility
Beyond Air has a beta of 0.21, indicating that its share price is 79% less volatile than the S&P 500. Comparatively, Orchestra BioMed has a beta of 0.52, indicating that its share price is 48% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current ratings and price targets for Beyond Air and Orchestra BioMed, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Beyond Air | 1 | 0 | 3 | 0 | 2.50 |
| Orchestra BioMed | 1 | 0 | 6 | 0 | 2.71 |
Beyond Air presently has a consensus price target of $105.00, suggesting a potential upside of 4,923.92%. Orchestra BioMed has a consensus price target of $13.17, suggesting a potential upside of 135.54%. Given Beyond Air’s higher possible upside, equities research analysts plainly believe Beyond Air is more favorable than Orchestra BioMed.
Insider and Institutional Ownership
31.5% of Beyond Air shares are owned by institutional investors. Comparatively, 53.2% of Orchestra BioMed shares are owned by institutional investors. 10.0% of Beyond Air shares are owned by insiders. Comparatively, 7.5% of Orchestra BioMed shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
Orchestra BioMed beats Beyond Air on 10 of the 13 factors compared between the two stocks.
About Beyond Air
Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.
About Orchestra BioMed
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company’s flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.
Receive News & Ratings for Beyond Air Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beyond Air and related companies with MarketBeat.com's FREE daily email newsletter.
